Inhalation of activated protein C: A possible new adjunctive intervention in acute respiratory distress syndrome by Heslet, Lars et al.
© 2007 Heslet et al, publisher and licensee Dove Medical Press Ltd.   This is an Open Access article 
which permits unrestricted noncommercial use, provided the original work is properly cited.
Biologics: Targets & Therapy 2007:1(4) 465–472 465
ORIGINAL RESEARCH
Inhalation of activated protein C: A possible 
new adjunctive intervention in acute respiratory 
distress syndrome
Lars Heslet1
Jakob Steen Andersen1
Henrik Sengeløv2
Björn Dahlbäck3
Jorgen Dalsgaard-Nielsen4
1Department of Intensive Care ITA 
4131; 2Department of Hematology L, 
University Hospital of Copenhagen, 
Rigshospitalet, Denmark; 3Department 
of Laboratory Medicin, Clinical 
Chemistry, Lund University, 
University Hospital, Malmö, Sweden; 
4Department of Clinical Biochemistry, 
Gentofte University Hospital, 
Hellerup, Denmark
Correspondence: Lars Heslet
Department of Intensive Care ITA 4131, 
University Hospital of Copenhagen, 
Rigshospitalet, Blegdamsvej 9, DK 2100 
Denmark
Tel (+45)28151922
Email heslet@image.dk
Abstract: Acute respiratory distress syndrome (ARDS) is a potential lethal disease. At present 
time no evidence based intervention reduces mortality. The pathophysiology of ARDS include 
intraalveolar ﬁ  brin deposition, hyperinﬂ  ammation and reduced cellular host defense in the 
airspace. The normal lung activates protein C (PC) to activated protein C (APC), in contrast to 
the ARDS lung where the PC-APC axis is disrupted. The lungs have targets for inhaled APC as 
illustrated by a patient case with ARDS, unresponsive to conventional therapy. After inhalation 
of 190 μg/kg of APC (Drotrecogin alpha activated) three times a day for seven days, a clear 
reduction in inﬁ  ltrates on chest X-ray and a 138% increase in oxygenation capacity as reﬂ  ected 
by the PaO2/FiO2 ratio was brought about. The patient, however, died later after cardiac arrest 
after suspected recurrence of the T-cell lymphoma. No local or systemic adverse effects was 
found related to the iAPC, during, after or at the time of death. It is suggested based on exist-
ing studies and the presented case that inhaled APC is a new treatment option in patients with 
ARDS – a hypothesis which should be substantiated in a larger series of ARDS patients.
Keywords: ARDS, activated protein C inhalation, pulmonary hemostasis, pulmonary host 
defense
Introduction
Despite improvements in ventilation strategies, acute respiratory distress syndrome 
(ARDS), which is the most severe form of acute lung injury (ALI), is associated 
with 40% (Girard and Bernard 2007) and a 80% mortality in mechanically ventilated 
hematological patients (Pène et al 2006).
Alveolar ﬁ  brin deposition is an important feature of ARDS. The alveolar epi-
thelium is capable of initiating intra-alveolar coagulation following exposure to 
inﬂ  ammatory stimuli and may thus contribute to intra-alveolar ﬁ  brin deposition 
in ARDS (Bastarache et al 2007). The mechanisms that contribute to disturbed 
alveolar ﬁ  brin turnover are localized tissue factor-mediated thrombin generation 
and depression of bronchoalveolar urokinase plasminogen activator (uPA)-mediated 
ﬁ  brinolysis caused by the increase of plasminogen activator inhibitors (Schultz et al 
2006). Furthermore, a reduced supply of uPA inhibits lung epithelial cell function, 
since uPA has been shown to activate major intracellular signaling pathways such 
as tyrosine phosphorylation of Stat3 (Shetty et al 2006). Further increased alpha 
2-antiplasmin levels shift the alveolar hemostatic balance towards a procoagulant 
state (Günther et al 2000).
The natural protein C anticoagulant pathway is a vital system that limits the activa-
tion of hemostasis and has anti-inﬂ  ammatory effects (Hancock et al 1995; Dahlback 
and Villoutreix 2006; Esmon 2006; Mosnier et al 2007). The alveolar epithelium may 
therefore modulate intra-alveolar ﬁ  brin deposition through activation of protein C.Biologics: Targets & Therapy 2007:1(4) 466
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In inﬂ  ammatory lung disease the pulmonary host defense is 
downregulated, as observed in ARDS (Grissell et al 2007).
It is therefore imperative that a new adjunctive 
intervention in ARDS does not further interfere with the 
immunocompetent cells of the lungs, ie, with alveolar 
macrophages or recruited neutrophils. Activated neutrophils 
accumulate in the lungs during severe infection and inﬂ  am-
mation and further contribute to pulmonary dysfunction and 
mortality (Abraham 2003).
These well described pathophysiological aspects of 
acute pulmonary inﬂ  ammation in ARDS with ﬁ  brin for-
mation, proinﬂ  ammatory cytokine production, pulmonary 
cellular host defense, and neutrophil recruitment are all 
potential targets of a new treatment paradigm such as 
inhaled APC.
We describe here for the ﬁ  rst time the effect of inhaled 
APC in a patient with severe ARDS.
Patient history
A 48-year-old woman was treated with chemotherapy for 
a T-cell lymphoma present in mediastinum, bone marrow, 
retroperitoneum, and in all peripheral lymph node regions. 
After ﬁ  ve courses of chemotherapy, a partial response with 
reduction in size of the lymphomas was noted.
While neutropenic after the last course of chemotherapy, 
she developed fever and clinical signs of pneumonia with 
lung inﬁ  ltrates on chest X-ray. One week earlier, she was 
found to be Epstein barr virus (EBV)–PCR positive in 
peripheral blood with a high titer (520,000 copies/mL).
The patient subsequently developed respiratory 
insufﬁ  ciency and was intubated and admitted to the intensive 
care unit (ICU), where she was mechanically ventilated. At 
the same time, the EBV-titer had dropped spontaneously to 
100,000 copies/mL, but when a suspected lymphoprolifera-
tive disorder induced by EBV was indicated, the patient was 
treated with anti-CD-20 antibody (Mabthera).
The patient fulﬁ  lled the criteria for severe ARDS with a 
PaO2/FiO2 ratio of 55 mmHg and chest X ray with diffuse 
inﬁ  ltrates. At ICU admittance she was diagnosed with septic 
shock in need of noradrenaline (NA) infusion combined with 
methylprednisolone infusion as a shock reversal therapy.
On ICU admission the patient had multi-organ dysfunc-
tion syndrome (MODS) with respiratory and hemodynamic 
failure, and liver and renal dysfunction. Administration of 
broad spectrum antibiotics began. On day 2 in the ICU, the 
PaO2/FiO2 ratio was unchanged and the patient was still 
in septic shock. Infectious biomarkers increased but no 
infectious microorganism was identiﬁ  ed at any time.
Lung mechanics were dominated by severely reduced 
compliance irrespective of any lung protective ventilator 
setting or recruitment procedures including positioning in a 
prone position or administration of prostacycline. The opti-
mal ventilator setting was pressure controlled mode with a 
PEEP 10 cm H2O and pressure level 25 cm H2O.
Blood gases throughout were characterized by respiratory 
acidosis with a pH = 7.29. Systemic steroid administration 
had no effect on pulmonary function.
Because of the patient’s acute life-threatening state as 
a result of severe hypoxemia and the lack of response to 
conventional intervention, an experimental therapy with 
inhalation of activated protein C (APC (drotrecogin alpha 
activated [Xigris®, Eli Lilly, USA]) was commenced on 
day 4. An institutional review board (IRB) of the National 
University Hospital of Copenhagen consented to initiate 
the intervention which was also accepted by the patient’s 
husband after informed consent. A dose schedule of 190 μg 
APC/kg 3 times a day was administered via a micropump 
nebulizer (Aeroneb®) which minimizes drug inactivation, in 
contrast to jet and ultrasound nebulizers which apply heat 
and shear stress.
The treatment was scheduled to last 7 days, ie, 21 doses 
in total. After 4 days (ICU day 8) there was a clear resolution 
of the inﬁ  ltrates on chest X ray and of the PaO2/FiO2 ratio, 
which increased from 55 to 83 mmHg. After 6 days the NA 
infusion was weaned off and the chest ﬁ  lm showed further 
reduction of inﬁ  ltrates. The PaO2/FiO2 ratio was further 
increased to 131 mmHg and then to 155 mmHg at the end 
of inhalation, with APC corresponding to a 138% increase 
(see Figure 1). After 7 days the renal and liver dysfunction 
was reduced and a stable circulation without need of vaso-
pressures was obtained.
No adverse effects of the APC inhalation therapy were 
observed and speciﬁ  cally no “bloody” lavage ﬂ  uid was seen 
from the tracheal tube. Bronchoalveolar lavage (BAL) and a 
transbronchial needle biopsy was performed in the ICU on 
day 14. The biopsy showed diffuse alveolar inﬂ  ammation 
corresponding to the organizing phase of diffuse alveolar 
damage, and signs of bronchiolitis affecting the bronchioli. 
There was no evidence of lymphoproliferative disease in the 
lung biopsy. BAL ﬂ  uid cultures were negative for bacteria, 
yeast, mold, and virus. On day 16, a CT scan of the abdomen 
showed new mediastinal and retroperitoneal lymph nodes. In 
spite of the temporary clinical improvement with improved 
oxygenation capacity and opacities on chest X-ray, the patient 
died in the ICU on day 22 from cardiac arrest. Postmortem 
section was not granted by her husband.Biologics: Targets & Therapy 2007:1(4) 467
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Discussion
Management of ARDS is difﬁ  cult due to the frequently life-
threatening hypoxemia (Suter 2006). For many years ARDS 
has been treated with corticosteroids, an approach which has 
now been shown to be disappointing (The National Heart, 
Lung, and Blood Institute Acute Respiratory Distress Syn-
drome (ARDS) Clinical Trials Network 2006). In this patient, 
however, the corticosteroids were administered as a shock-
reversal therapy and not as a symptomatic ARDS therapy. 
Further symptomatic intervention in ARDS has been the 
subject of many other randomised studies including treatment 
options such as antioxidants, inhaled surfactant and vasodila-
tors like nitric oxide, and conservative ﬂ  uid management of 
these critically ill patients. These interventions were unsuc-
cessful in reducing the mortality of this potentially lethal 
disease (Wheeler and Bernard 2007). In spite of therapy to 
treat any underlying causative factor, standard symptomatic 
interventions in ARDS with lung protective ventilation, lung 
recruitment, use of an inhaled vasodilator with prostacyclin 
(PGI2), and positioning in the prone position, the patient did 
not respond in respect to respiratory failure or oxygenation 
capacity. The ARDS condition also failed to respond to sys-
temic steroid therapy. The APC in the present case history 
was not administered because Severe Sepsis was indicated, 
but as an experimental therapy for severe pulmonary dysfunc-
tion. Since this is a “ﬁ  rst in man” therapy, and no evidence 
based therapy for ARDS exists (Wheeler and Bernard 2007), 
an experimental attempt was initiated in order to modify or 
treat the diffuse lung injury. The therapy with inhaled APC 
for seven days seemed to demonstrate a clear response, 
with reduction in opacities on chest X ray and with a 138% 
increase in oxygenation capacity on day 7 as reﬂ  ected by 
the PaO2/FiO2 ratio.
This patient died suddenly from a cardiac arrest. Recur-
rence of malignant lymphoma may have contributed to this 
event. Another component of the negative outcome might 
have been the result of initiating the inhalation with APC 
at a too advanced and less responsive phase of the ARDS 
course. At the time of death, there was no systemic or local 
pulmonary adverse effects of iAPC, ie, no signs of bleeding 
systemically or locally in the lung, ie, alveolar hemorrhage 
was not present.
ARDS and APC
Endogenous protein C can be activated by thrombomodulin 
(TM) in the distal airways as well as in the microcirculation 
(Dahlback and Villoutreix 2006; Esmon 2006; Mosnier et al 
2007). In the periphery of the lung an epithelial protein C 
receptor (EPCR), located on alveolar type I and II cells in 
the small airways mediates the endogenous pulmonary APC 
response (Wang et al 2007). Inﬂ  ammation induced by lipo-
polysaccharide (LPS) causes suppression of the PC pathway, 
as indicated by increased concentration of soluble TM and 
decreased concentration of PC and APC in bronchoalveolar 
lavage ﬂ  uid (BALF) (Maris et al 2007).
In a study of 45 patients with ALI/ARDS, resulting 
from septic and nonseptic causes, the concentration of TM 
in BALF was more than twofold higher than simultaneous 
Figure 1 Chest X-ray of the patient at the start of the inhalation of APC (A) and after 7 days of inhalation with APC (B).Biologics: Targets & Therapy 2007:1(4) 468
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plasma levels, suggesting that local production in the lung, 
and increased edema ﬂ  uid TM level, was associated with 
worse clinical outcomes (Ware et al 2003). Deﬁ  cient intra-
alveolar activation of protein C may aggravate the sever-
ity of ARDS by enhancing ﬁ  brin deposition via localized 
pulmonary tissue factor-mediated thrombin generation, 
and depression of bronchoalveolar urokinase plasminogen 
activator-mediated fibrinolysis, caused by the increase 
of plasminogen activator inhibitor (PAI)-1 (Schultz et al 
2006). Therefore, the protein C system may be a potential 
therapeutic target, using supplementary inhalation of APC 
in patients with ALI/ARDS to compensate for the innate 
APC deﬁ  ciency.
In mice exposed to LPS, inhalation of APC was 
associated with a dose-dependent decrease in coagulation, 
inﬂ  ammation markers in BAL ﬂ  uid, reduced protein leakage 
into the alveolar space and improved lung function (Slofstra 
et al 2006).
These findings provide new evidence that inhaled 
activated protein C may modify alveolar ﬁ  brin deposition in 
ARDS (Suter 2006) as seen in the positive clinical response 
in the present patient.
Intravenous vs inhalation administration 
of APC
Intravenously administered recombinant human activated 
protein C (rhAPC) in acute lung injury after bacterial chal-
lenge signiﬁ  cantly attenuated the fall in PaO2/FiO2 ratio, 
improved the lung mechanics and limited the induced lung 
tissue injury (van der Poll et al 2005). The APC, however, 
most likely exerts its effect both through inhibition of coagu-
lation, and by inhibiting inﬂ  ammation and apoptosis, by 
binding to its receptor EPCR, located in the airspaces. This 
result implies that the multiple targets for APC in ARDS are 
located in the airspaces (see Figure 1).
In order to obtain a sufﬁ  ciently high alveolar concentration 
of APC, the IV dose rate must be sufﬁ  ciently high, taking 
into account several factors. In order to reach sufﬁ  cient 
alveolar APC concentration, the IV dosing must overcome 
the inactivation of the two serpins, alpha1-anti trypsin and 
the protein C inhibitor (PCI), and also the very short half-
life of 13 minutes of APC when administered intravenously 
(Bernard et al 2001a). Furthermore, the APC molecule is quite 
large, ie, 55 kDa with 461 amino acids with a corresponding 
high diffusion barrier across the alveolo-capillary membrane 
to the airway receptors. All these factors limit the efﬁ  ciency 
of an IV dose when the target is the airways. Once the IV 
dose reaches the air space, APC is further metabolised by 
alveolar proteolytic enzymes. It therefore seems rational 
also to inhale APC when the therapeutic target is the lung 
airspaces in acute respiratory injury like ARDS, in order to 
overcome the adverse effects of IV dosing.
The dosing of inhaled APC in the present patient case 
was based on the same dosing regime as in the PROWESS 
study (Bernard et al 2001b) of 24 μg/kg/hr, corresponding 
to a total dose for 24 hours of 576 μg/kg; divided into three 
inhalation doses. This treatment corresponds to a single 
inhaled dose of 190 μg/kg rAPC.
We predicted that a dose of 190 μg/kg per inhalation, 
would give rise to a suitably lower alveolar concentration, 
corresponding to 20% of the inhaled APC dose deposited 
using the micropump nebulizer Aeroneb (Dubus et al 2005). 
The metabolism of APC has been well described; however, 
the intrapulmonary metabolism after inhaled APC has not 
been elucidated.
An increased metabolism of APC is likely in inﬂ  amma-
tory pulmonary conditions, because elevated levels of neu-
trophil, and macrophage-derived proteolytic enzymes like 
neutrophil elastase and cathepsin, have been documented 
in ARDS patients (Sallenave et al 1999). Furthermore, 
because the neutralizing protein C Inhibitor (PCI) is a 
smaller molecule, it readily diffuses into the alveolar space 
where it subsequently neutralizes APC, a process which 
is enhanced in inﬂ  ammatory lung disease, as revealed by 
increased concentrations of bronchoalveolar lavage ﬂ  uid 
levels of TAFI and PCI (Fujimoto et al 2003). A high 
APC dose would give rise to a ‘spill over’ of drug to the 
systemic circulation with detectable increase in APTT. 
Such an increase however could not be demonstrated in the 
present patient. In short, it seems that an inhaled dose of 
190 μg/kg in each inhalation is a realistic moderate dose. 
In a systematic proof of concept study, APC kinetics will 
be included.
We chose to extend the dose length from the 4-day dose 
scheme applied in the prowess study (Bernard et al 2001b) 
to 7 days in the present patient, taking into account the 
ongoing pathophysiology of the ARDS and the relatively 
long recovery time of ARDS.
In the present study a micropump nebulizer was selected, 
because it has been shown to produce aerosolized protein 
samples which retain both structural integrity and biological 
activity (Oette et al 2004). This decision is in keeping with 
the study of aerosolized APC using the same nebulizer where 
coagulation factors like TAT complex and the cytokines TNF 
and IL-6 were reduced, corresponding to a preserved activity 
of APC aerosol (Slofstra et al 2006). It is therefore likely that Biologics: Targets & Therapy 2007:1(4) 469
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the inhaled APC retains its activity after aerosolization using 
a micropump nebulizer.
APC and diffuse lung injury (DLI)
Pulmonary complications like noninfectious diffuse lung 
injury (DLI) in hematological patients like the patient 
case – a severe form of ARDS – has a high incidence in 
hematological patients (Krowka et al 1985). The histopathol-
ogy of DLI includes diffuse epithelial alveolar damage with 
hyaline membranes, lymphocytic bronchiolar inﬂ  ammation 
and bronchiolitis obliterans with organizing pneumonia 
(BOOP) (Watkins et al 2005). The survival rate for critically 
ill hematological patients with DLI requiring mechanical 
ventilation has been reported to be well below 20% (Shorr 
et al 1999; Pène et al 2006). This patient died suddently from 
a cardiac arrest; both the ARDS and the malignant lymphoma 
may have contributed to this event. Another component of 
the negative outcome was the initiation of the inhalation 
with APC at a late and less responsive phase of the ARDS 
course. At the time of death, there was no systemic or local 
pulmonary adverse effects of iAPC with no signs of bleeding 
systemically or locally in the lung, ie, alveolar hemorrhage 
was not present.
This patient had a component of bronchiolitis as seen in the 
lung biopsy. The pulmonary clinical response in the present 
case could partially be explained by the immunomodulatory 
Figure 2 Illustration of the potential multiple effects of inhaled activated protein C (iAPC) in ARDS in relation to the underlying pathophysiology of ARDS. Inhaled APC (1) 
inhibits coagulation (Factor Va and VIIIa) (2) and enhances ﬁ  brinolysis (3). Further iAPC has an anti-inﬂ  ammatory effect and anti-apoptotic effect exerted via its APC recep-
tor (EPCR) on the alveolar macrophage, epithelial cell and ﬁ  nally at the site of small airways (4) and reduces tissue factor expression via inhibition of the transnuclear NFKB 
translocation (5). Finally iAPC inhibits neutrocyte recruitment from the circulation to the airspaces (6) without interfering with their host function. The numbers 1–6 refer 
to the multiple points of action of iAPC.
Abbreviations: AF,   Alveolar macrophage; EPCR, Epithelial protein C receptor; FVII, Coagulation factor VII; SA cell, Mucosal cell of small airways.Biologics: Targets & Therapy 2007:1(4) 470
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effect of activated protein C, which has been shown to reduce 
the peribronchiolar lymphocytic migration (Feistritzer et al 
2006). This effect matches the ﬁ  ndings of an inhibition of 
immunologic and inﬂ  ammatory responses induced by Th2 
produced cytokines in a mouse model of asthma after intra-
tracheally administered APC (Yuda et al 2004).
Pulmonary host defense and APC
The pulmonary host defense is reduced in ARDS with 
increased apoptosis gene expression and reduced TLR gene 
mRNA expression in airway cells (Grissell et al 2007). 
Mechanical ventilation with high FiO2, results in further 
impairment in pulmonary innate immunity through sup-
pression of local GM-CSF expression of alveolar epithelial 
cells due to hyperoxic stress (Baleeiro et al 2006). It is 
therefore important when introducing a novel therapy such 
as aerosolized APC, that it does not further interfere with the 
pulmonary host defense.
Inhalation of APC interacts with the inﬂ  ammatory and 
coagulation, a response which may impede the primary host 
defense mechanisms (Opal and Esmon 2003). Prior to intro-
duction of a new therapy like inhalation of APC, evaluation 
of host defense, such as phagocytotic activity of alveolar 
macrophages, apoptosis of cellular host defense and expres-
sion of alveolar recognition receptors, ie, Toll-like receptors 
must be taken into account. An in-vitro study of activated 
protein C showed that the lifespan of human macrophages 
was prolonged, with unaltered phagocytotic function towards 
both Gram-positive and Gram-negative bacteria, and persis-
tent adherence capabilities to LPS stimulated cells, promot-
ing and maintaining antimicrobial properties while limiting 
damage to host tissue (Stephenson et al 2006). There is no 
documentation of the interference of APC with TLR receptor 
expression, but in the study of LPS challenge, APC reduced 
mortality in murine endotoxemia and models of severe sepsis 
(Grifﬁ  n et al 2007) and in the study of pneumonia, APC did 
not seem to interact with bacterial clearance (Choi et al 2007). 
This study also showed that administration of APC improved 
the outcome for patients with severe sepsis in spite of positive 
cultures in a majority of the included septic patients (Bernard 
et al 2001b). Finally APC has an antiapoptotic effect (Esmon 
2006) which is considered an essential therapeutic target 
treating infectious conditions (Doreen et al 2007).
Accumulation of activated neutrophils into the airspaces 
during severe infection contributes to organ dysfunction in 
ARDS. It has been shown that APC modulates the neutrophil 
responses due to the expression of an APC receptor on these 
cells (Sturn et al 2003), and that intravenous APC reduced 
leukocyte accumulation, and neutrophil chemotaxis into 
the airspaces without inducing immunosuppression (Nick 
et al 2004).
Therefore, in general APC does not seem to have a 
negative affect on pulmonary host defense. On the contrary, 
inhaled APC most likely represents a valuable new treatment 
which reduces severity of ARDS, but without interfering with 
the pulmonary host defense.
Conclusion
A new symptomatic therapy, involving intrapulmonary 
administration of aerosolized APC is proposed and illustrated 
by a case with a positive pulmonary clinical response. No 
adverse effects could be registered during the 7-day therapy. 
From a theoretical viewpoint, inhaled APC with its antico-
agulatory, proﬁ  brinolytic, antiinﬂ  ammatory and antiapoptotic 
effect, including reduced neutrophil recruitment into the 
airspaces, has all the essential properties to counteract the 
pathophysiological changes seen in ARDS. Furthermore, 
inhaled APC seems not to interfere with the pulmonary host 
defense. Therefore we suggest that ARDS is best treated 
from the “air side” with aerosolized APC, because the innate 
intrapulmonary PC-APC axis is disrupted in inﬂ  ammatory 
lung conditions like ARDS and the multiple effects of iAPC 
are mediated via the targets in the airspaces. We conclude that 
inhaled APC could become a new treatment option in patients 
with ALI or ARDS. This hypothesis should be substantiated 
in a study of a larger series of ARDS patients.
Key messages
–  Inhaled APC has multiple effects to counteract the well 
described pathophysiological ARDS changes, as illus-
trated in a patient case.
–  It seems that inhaled APC does not interfere with pulmo-
nary host defense.
–  Inhaled APC might be a new ideal adjunctive intervention 
in ARDS combined with therapy of underlying disease, 
a suggestion which should be substantiated in a larger 
series of patients.
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